Amgen Phase 3: Xaluritamig vs Cabazitaxel or Second ARDT in mCRPC (Prostate Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find the most effective, safe dose of an experimental drug called xaluritamig (the study drug). We want to know how well this drug works compared to the standard drugs for people who have metastatic castration-resistant prostate cancer.
Cáncer de próstata
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with adenocarcinoma of the prostate
- Have had a previous orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone
- Have received previous treatment with at least one ARDT and one taxane therapy
- Have never received STEAP1-targeted therapy
For more information, contact the study team at julia.hurrelbrink@duke.edu
What is Involved?
If you choose to join this study, you will get a random assignment to either:
- Get the study drug; OR
- Get the standard treatment for this type of cancer
You will have a 2-in-3 chance of getting the study drug and a 1-in-3 chance of getting the standard treatment. The standard treatment will involve taking a drug called cabazitaxel or 1 of 2 drugs classified as androgen receptor directed therapies (enzalutamide or abiraterone acetate). You and the study doctor will discuss which standard therapy is most appropriate before you get your study assignment.
You will take part in the study for up to 56 months, including a minimum of 36 months of drug regimen and follow-up. The amount of time you take the study drug or standard treatment will vary and depends on how well you tolerate or respond to your assigned study regimen.
Study Details
